Clinical trial
Safety, Tolerability and Pharmacodynamic Effects of Sublingual Immunotherapy…
NCT00396149 · Stallergenes Greer, Industry · Completed
Key facts
| NCT number | NCT00396149 |
|---|---|
| Title | Safety, Tolerability and Pharmacodynamic Effects of Sublingual Immunotherapy (Tablets) With Recombinant Bet v1 |
| Official title | A Phase I Study to Investigate the Safety, Tolerability and Pharmacodynamic Effects of SLIT(Tablets) With Recombinant Bet v1 Given in Single Rising Doses and in Higher Multi Dose Regimens to Subjects Sensitised to Birch Pollen |
| Lead sponsor | Stallergenes Greer, Industry |
| Collaborators | Quintiles, Inc. Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Birch Pollen-Related Rhinoconjunctivitis, Rhinitis, Allergic, Seasonal |
| Intervention type | Biological |
| Interventions | Placebo, rBet v 1 |
| Enrollment | 57 |
| Start date | Nov 1, 2006 |
| Primary completion | Mar 1, 2007 |
| Completion | Jun 1, 2007 |
| First posted | Nov 6, 2006 |
| Last update posted | Jun 27, 2013 |
| Countries | Denmark |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: